Dechert Advises Royalty Pharma on Acquisition of Royalty Interest from GSK
April 05, 2021
Dechert has advised Royalty Pharma plc on IP-related matters in its acquisition of a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the U.S. and Europe.
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
The Dechert team advising Royalty Pharma includes intellectual property partner Carl A. Morales, Ph.D., associate Blaine M. Hackman, Ph.D. and patent agent Todd K. Macklin, Ph.D.
About Dechert
Dechert is a leading global law firm with 25 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for all clients.
Related Professionals
